#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=6. Challenges in MSC Translation into Clinical Practice :
1-1	0-2	6.	abstract[1]	new[1]	_	_
1-2	3-13	Challenges	abstract[1]	new[1]	_	_
1-3	14-16	in	abstract[1]	new[1]	_	_
1-4	17-20	MSC	abstract[1]|place|abstract[3]	new[1]|new|new[3]	coref|coref	3-17|3-17
1-5	21-32	Translation	abstract[1]|abstract[3]	new[1]|new[3]	_	_
1-6	33-37	into	abstract[1]|abstract[3]	new[1]|new[3]	_	_
1-7	38-46	Clinical	abstract[1]|abstract[3]|abstract[4]	new[1]|new[3]|new[4]	_	_
1-8	47-55	Practice	abstract[1]|abstract[3]|abstract[4]	new[1]|new[3]|new[4]	_	_
1-9	56-57	:	_	_	_	_

#Text=The Bone Disease Framework
2-1	58-61	The	abstract[7]	new[7]	_	_
2-2	62-66	Bone	person|abstract[7]	new|new[7]	coref	21-1
2-3	67-74	Disease	abstract|abstract[7]	new|new[7]	_	_
2-4	75-84	Framework	abstract[7]	new[7]	_	_

#Text=Other interesting aspects and new perspectives in the field of tissue regeneration and applicative use of MSC are strictly related to their potential to tackle the increase in bone diseases related with the extended life expectancy .
3-1	85-90	Other	abstract[8]	new[8]	_	_
3-2	91-102	interesting	abstract[8]	new[8]	_	_
3-3	103-110	aspects	abstract[8]	new[8]	_	_
3-4	111-114	and	_	_	_	_
3-5	115-118	new	abstract[9]	new[9]	_	_
3-6	119-131	perspectives	abstract[9]	new[9]	_	_
3-7	132-134	in	abstract[9]	new[9]	_	_
3-8	135-138	the	abstract[9]|abstract[10]	new[9]|new[10]	_	_
3-9	139-144	field	abstract[9]|abstract[10]	new[9]|new[10]	_	_
3-10	145-147	of	abstract[9]|abstract[10]	new[9]|new[10]	_	_
3-11	148-154	tissue	abstract[9]|abstract[10]|object|abstract[12]|abstract[13]	new[9]|new[10]|new|new[12]|new[13]	ana|coref|coref|ana|coref|coref|ana|coref|coref	3-22[0_13]|5-16[38_0]|9-24[0_12]|3-22[0_13]|5-16[38_0]|9-24[0_12]|3-22[0_13]|5-16[38_0]|9-24[0_12]
3-12	155-167	regeneration	abstract[9]|abstract[10]|abstract[12]|abstract[13]	new[9]|new[10]|new[12]|new[13]	_	_
3-13	168-171	and	abstract[9]|abstract[10]|abstract[13]	new[9]|new[10]|new[13]	_	_
3-14	172-183	applicative	abstract[9]|abstract[10]|abstract[13]|abstract[14]	new[9]|new[10]|new[13]|new[14]	_	_
3-15	184-187	use	abstract[9]|abstract[10]|abstract[13]|abstract[14]	new[9]|new[10]|new[13]|new[14]	_	_
3-16	188-190	of	abstract[9]|abstract[10]|abstract[13]|abstract[14]	new[9]|new[10]|new[13]|new[14]	_	_
3-17	191-194	MSC	abstract[9]|abstract[10]|abstract[13]|abstract[14]|object	new[9]|new[10]|new[13]|new[14]|giv	coref	10-11
3-18	195-198	are	_	_	_	_
3-19	199-207	strictly	_	_	_	_
3-20	208-215	related	_	_	_	_
3-21	216-218	to	_	_	_	_
3-22	219-224	their	abstract|abstract[17]	giv|new[17]	coref|coref	29-27[301_0]|29-27[301_0]
3-23	225-234	potential	abstract[17]	new[17]	_	_
3-24	235-237	to	_	_	_	_
3-25	238-244	tackle	_	_	_	_
3-26	245-248	the	abstract[18]	new[18]	_	_
3-27	249-257	increase	abstract[18]	new[18]	_	_
3-28	258-260	in	abstract[18]	new[18]	_	_
3-29	261-265	bone	abstract[18]|object|abstract[20]	new[18]|new|new[20]	coref|coref|coref|coref	4-6|4-6[25_20]|4-6|4-6[25_20]
3-30	266-274	diseases	abstract[18]|abstract[20]	new[18]|new[20]	_	_
3-31	275-282	related	_	_	_	_
3-32	283-287	with	_	_	_	_
3-33	288-291	the	abstract[22]	new[22]	_	_
3-34	292-300	extended	abstract[22]	new[22]	_	_
3-35	301-305	life	abstract|abstract[22]	new|new[22]	_	_
3-36	306-316	expectancy	abstract[22]	new[22]	_	_
3-37	317-318	.	_	_	_	_

#Text=Indeed , in many countries bone diseases are becoming a relevant cause of disability , even if they are acute , such as fractures , or chronic , such as osteoporosis and tumours .
4-1	319-325	Indeed	_	_	_	_
4-2	326-327	,	_	_	_	_
4-3	328-330	in	_	_	_	_
4-4	331-335	many	place[23]	new[23]	_	_
4-5	336-345	countries	place[23]	new[23]	_	_
4-6	346-350	bone	object|abstract[25]	giv|giv[25]	ana|coref|ana|coref	4-18[0_25]|5-16|4-18[0_25]|5-16
4-7	351-359	diseases	abstract[25]	giv[25]	_	_
4-8	360-363	are	_	_	_	_
4-9	364-372	becoming	_	_	_	_
4-10	373-374	a	_	_	_	_
4-11	375-383	relevant	_	_	_	_
4-12	384-389	cause	_	_	_	_
4-13	390-392	of	_	_	_	_
4-14	393-403	disability	abstract	new	_	_
4-15	404-405	,	_	_	_	_
4-16	406-410	even	_	_	_	_
4-17	411-413	if	_	_	_	_
4-18	414-418	they	abstract	giv	coref	23-34[257_0]
4-19	419-422	are	_	_	_	_
4-20	423-428	acute	_	_	_	_
4-21	429-430	,	_	_	_	_
4-22	431-435	such	_	_	_	_
4-23	436-438	as	_	_	_	_
4-24	439-448	fractures	event	new	_	_
4-25	449-450	,	_	_	_	_
4-26	451-453	or	_	_	_	_
4-27	454-461	chronic	_	_	_	_
4-28	462-463	,	_	_	_	_
4-29	464-468	such	_	_	_	_
4-30	469-471	as	_	_	_	_
4-31	472-484	osteoporosis	abstract	new	_	_
4-32	485-488	and	_	_	_	_
4-33	489-496	tumours	object	new	_	_
4-34	497-498	.	_	_	_	_

#Text=In any case these pathologies require treatments to enhance the healing and regenerative capacity of bone tissue .
5-1	499-501	In	_	_	_	_
5-2	502-505	any	event[31]	new[31]	coref	14-2[132_31]
5-3	506-510	case	event[31]	new[31]	_	_
5-4	511-516	these	abstract[32]	new[32]	_	_
5-5	517-528	pathologies	abstract[32]	new[32]	_	_
5-6	529-536	require	_	_	_	_
5-7	537-547	treatments	abstract	new	_	_
5-8	548-550	to	_	_	_	_
5-9	551-558	enhance	_	_	_	_
5-10	559-562	the	abstract[34]|abstract[35]	new[34]|new[35]	coref|coref|coref|coref	9-21[80_34]|9-21[81_35]|9-21[80_34]|9-21[81_35]
5-11	563-570	healing	abstract[34]|abstract[35]	new[34]|new[35]	_	_
5-12	571-574	and	abstract[35]	new[35]	_	_
5-13	575-587	regenerative	abstract[35]|abstract[36]	new[35]|new[36]	_	_
5-14	588-596	capacity	abstract[35]|abstract[36]	new[35]|new[36]	_	_
5-15	597-599	of	abstract[35]|abstract[36]	new[35]|new[36]	_	_
5-16	600-604	bone	abstract[35]|abstract[36]|object|object[38]	new[35]|new[36]|giv|giv[38]	coref|coref|coref|coref	6-7|8-31[0_38]|6-7|8-31[0_38]
5-17	605-611	tissue	abstract[35]|abstract[36]|object[38]	new[35]|new[36]|giv[38]	_	_
5-18	612-613	.	_	_	_	_

#Text=The common therapeutic strategies based on bone grafting ( autografts or allografts ) show some disadvantages .
6-1	614-617	The	abstract[39]	new[39]	coref	9-16[78_39]
6-2	618-624	common	abstract[39]	new[39]	_	_
6-3	625-636	therapeutic	abstract[39]	new[39]	_	_
6-4	637-647	strategies	abstract[39]	new[39]	_	_
6-5	648-653	based	_	_	_	_
6-6	654-656	on	_	_	_	_
6-7	657-661	bone	object|object[41]	giv|new[41]	appos|coref|appos|coref	6-10[42_41]|7-6|6-10[42_41]|7-6
6-8	662-670	grafting	object[41]	new[41]	_	_
6-9	671-672	(	_	_	_	_
6-10	673-683	autografts	object[42]	giv[42]	coref	7-1[0_42]
6-11	684-686	or	object[42]	giv[42]	_	_
6-12	687-697	allografts	object[42]	giv[42]	_	_
6-13	698-699	)	_	_	_	_
6-14	700-704	show	_	_	_	_
6-15	705-709	some	abstract[43]	new[43]	coref	9-4[0_43]
6-16	710-723	disadvantages	abstract[43]	new[43]	_	_
6-17	724-725	.	_	_	_	_

#Text=Autografts are limited by the bone volume that can be harvested from the iliac crest and present surgical risks such as bleeding , inflammation , infection , chronic pain , damage at the donor site and morbidity .
7-1	726-736	Autografts	event	giv	coref	8-1
7-2	737-740	are	_	_	_	_
7-3	741-748	limited	_	_	_	_
7-4	749-751	by	_	_	_	_
7-5	752-755	the	quantity[46]	new[46]	_	_
7-6	756-760	bone	object|quantity[46]	giv|new[46]	coref	9-21
7-7	761-767	volume	quantity[46]	new[46]	_	_
7-8	768-772	that	_	_	_	_
7-9	773-776	can	_	_	_	_
7-10	777-779	be	_	_	_	_
7-11	780-789	harvested	_	_	_	_
7-12	790-794	from	_	_	_	_
7-13	795-798	the	object[48]	new[48]	coref	24-23[265_48]
7-14	799-804	iliac	person|object[48]	new|new[48]	coref	24-24
7-15	805-810	crest	object[48]	new[48]	_	_
7-16	811-814	and	_	_	_	_
7-17	815-822	present	abstract[49]	new[49]	coref	20-51[0_49]
7-18	823-831	surgical	abstract[49]	new[49]	_	_
7-19	832-837	risks	abstract[49]	new[49]	_	_
7-20	838-842	such	abstract[49]	new[49]	_	_
7-21	843-845	as	abstract[49]	new[49]	_	_
7-22	846-854	bleeding	abstract[49]	new[49]	_	_
7-23	855-856	,	abstract[49]	new[49]	_	_
7-24	857-869	inflammation	abstract[49]|abstract	new[49]|new	_	_
7-25	870-871	,	abstract[49]	new[49]	_	_
7-26	872-881	infection	abstract[49]|event	new[49]|new	_	_
7-27	882-883	,	abstract[49]	new[49]	_	_
7-28	884-891	chronic	abstract[49]|abstract[52]	new[49]|new[52]	_	_
7-29	892-896	pain	abstract[49]|abstract[52]	new[49]|new[52]	_	_
7-30	897-898	,	abstract[49]	new[49]	_	_
7-31	899-905	damage	abstract[49]|abstract[53]	new[49]|new[53]	_	_
7-32	906-908	at	abstract[49]|abstract[53]	new[49]|new[53]	_	_
7-33	909-912	the	abstract[49]|abstract[53]|place[55]	new[49]|new[53]|new[55]	coref	24-29[266_55]
7-34	913-918	donor	abstract[49]|abstract[53]|person|place[55]	new[49]|new[53]|new|new[55]	_	_
7-35	919-923	site	abstract[49]|abstract[53]|place[55]	new[49]|new[53]|new[55]	_	_
7-36	924-927	and	abstract[49]|abstract[53]	new[49]|new[53]	_	_
7-37	928-937	morbidity	abstract[49]|abstract[53]|event	new[49]|new[53]|new	coref	11-16[98_0]
7-38	938-939	.	_	_	_	_

#Text=Allografts also have some limitations , such as the lack of donors , high costs , the need for sterilization and the risk of infectious agent transmission or immune mediated tissue rejection .
8-1	940-950	Allografts	object	giv	_	_
8-2	951-955	also	_	_	_	_
8-3	956-960	have	_	_	_	_
8-4	961-965	some	abstract[58]|abstract[59]	new[58]|new[59]	coref|coref|coref|coref	9-1[71_58]|9-1[72_59]|9-1[71_58]|9-1[72_59]
8-5	966-977	limitations	abstract[58]|abstract[59]	new[58]|new[59]	_	_
8-6	978-979	,	abstract[58]|abstract[59]	new[58]|new[59]	_	_
8-7	980-984	such	abstract[58]|abstract[59]	new[58]|new[59]	_	_
8-8	985-987	as	abstract[58]|abstract[59]	new[58]|new[59]	_	_
8-9	988-991	the	abstract[58]|abstract[59]|abstract[60]	new[58]|new[59]|new[60]	_	_
8-10	992-996	lack	abstract[58]|abstract[59]|abstract[60]	new[58]|new[59]|new[60]	_	_
8-11	997-999	of	abstract[58]|abstract[59]|abstract[60]	new[58]|new[59]|new[60]	_	_
8-12	1000-1006	donors	abstract[58]|abstract[59]|abstract[60]|person	new[58]|new[59]|new[60]|new	_	_
8-13	1007-1008	,	abstract[58]|abstract[59]|abstract[60]	new[58]|new[59]|new[60]	_	_
8-14	1009-1013	high	abstract[58]|abstract[59]|abstract[60]|abstract[62]	new[58]|new[59]|new[60]|new[62]	coref	20-49[207_62]
8-15	1014-1019	costs	abstract[58]|abstract[59]|abstract[60]|abstract[62]	new[58]|new[59]|new[60]|new[62]	_	_
8-16	1020-1021	,	abstract[59]	new[59]	_	_
8-17	1022-1025	the	abstract[59]|abstract[63]	new[59]|new[63]	coref	9-12[77_63]
8-18	1026-1030	need	abstract[59]|abstract[63]	new[59]|new[63]	_	_
8-19	1031-1034	for	abstract[59]|abstract[63]	new[59]|new[63]	_	_
8-20	1035-1048	sterilization	abstract[59]|abstract[63]|abstract	new[59]|new[63]|new	_	_
8-21	1049-1052	and	abstract[59]|abstract[63]	new[59]|new[63]	_	_
8-22	1053-1056	the	abstract[59]|abstract[63]|abstract[65]	new[59]|new[63]|new[65]	_	_
8-23	1057-1061	risk	abstract[59]|abstract[63]|abstract[65]	new[59]|new[63]|new[65]	_	_
8-24	1062-1064	of	abstract[59]|abstract[63]|abstract[65]	new[59]|new[63]|new[65]	_	_
8-25	1065-1075	infectious	abstract[59]|abstract[63]|abstract[65]|abstract[67]	new[59]|new[63]|new[65]|new[67]	_	_
8-26	1076-1081	agent	abstract[59]|abstract[63]|abstract[65]|person|abstract[67]	new[59]|new[63]|new[65]|new|new[67]	_	_
8-27	1082-1094	transmission	abstract[59]|abstract[63]|abstract[65]|abstract[67]	new[59]|new[63]|new[65]|new[67]	_	_
8-28	1095-1097	or	abstract[59]|abstract[63]|abstract[65]	new[59]|new[63]|new[65]	_	_
8-29	1098-1104	immune	abstract[59]|abstract[63]|abstract[65]|abstract	new[59]|new[63]|new[65]|new	_	_
8-30	1105-1113	mediated	abstract[59]|abstract[63]|abstract[65]	new[59]|new[63]|new[65]	_	_
8-31	1114-1120	tissue	abstract[59]|abstract[63]|abstract[65]|object|abstract[70]	new[59]|new[63]|new[65]|giv|new[70]	coref|coref	12-15[109_0]|12-15[109_0]
8-32	1121-1130	rejection	abstract[59]|abstract[63]|abstract[65]|abstract[70]	new[59]|new[63]|new[65]|new[70]	_	_
8-33	1131-1132	.	_	_	_	_

#Text=These limitations and disadvantages associated with auto- and allograft approaches indicate a clinical need for alternative therapeutic strategies aimed at bone healing and regeneration .
9-1	1133-1138	These	abstract[71]|abstract[72]	giv[71]|giv[72]	coref|coref	19-1[179_71]|19-1[179_71]
9-2	1139-1150	limitations	abstract[71]|abstract[72]	giv[71]|giv[72]	_	_
9-3	1151-1154	and	abstract[72]	giv[72]	_	_
9-4	1155-1168	disadvantages	abstract[72]|abstract	giv[72]|giv	_	_
9-5	1169-1179	associated	_	_	_	_
9-6	1180-1184	with	_	_	_	_
9-7	1185-1190	auto-	abstract|abstract[76]	new|new[76]	_	_
9-8	1191-1194	and	abstract[76]	new[76]	_	_
9-9	1195-1204	allograft	object|abstract[76]	new|new[76]	_	_
9-10	1205-1215	approaches	abstract[76]	new[76]	_	_
9-11	1216-1224	indicate	_	_	_	_
9-12	1225-1226	a	abstract[77]	giv[77]	coref	20-37[202_77]
9-13	1227-1235	clinical	abstract[77]	giv[77]	_	_
9-14	1236-1240	need	abstract[77]	giv[77]	_	_
9-15	1241-1244	for	abstract[77]	giv[77]	_	_
9-16	1245-1256	alternative	abstract[77]|abstract[78]	giv[77]|giv[78]	_	_
9-17	1257-1268	therapeutic	abstract[77]|abstract[78]	giv[77]|giv[78]	_	_
9-18	1269-1279	strategies	abstract[77]|abstract[78]	giv[77]|giv[78]	_	_
9-19	1280-1285	aimed	_	_	_	_
9-20	1286-1288	at	_	_	_	_
9-21	1289-1293	bone	object|abstract[80]|abstract[81]	giv|giv[80]|giv[81]	coref|coref|coref|coref|coref|coref	10-30|16-22[155_80]|10-30|16-22[155_80]|10-30|16-22[155_80]
9-22	1294-1301	healing	abstract[80]|abstract[81]	giv[80]|giv[81]	_	_
9-23	1302-1305	and	abstract[81]	giv[81]	_	_
9-24	1306-1318	regeneration	abstract[81]|abstract	giv[81]|giv	coref	13-10[120_0]
9-25	1319-1320	.	_	_	_	_

#Text=Thus , new biomaterials and scaffolds , in association with MSC and growth factors , having requirements of biocompatibility , osteoinductive and osteoconductive properties , are investigated to improve bone repair .
10-1	1321-1325	Thus	_	_	_	_
10-2	1326-1327	,	_	_	_	_
10-3	1328-1331	new	substance[83]	new[83]	_	_
10-4	1332-1344	biomaterials	substance[83]	new[83]	_	_
10-5	1345-1348	and	_	_	_	_
10-6	1349-1358	scaffolds	object[84]	new[84]	_	_
10-7	1359-1360	,	object[84]	new[84]	_	_
10-8	1361-1363	in	object[84]	new[84]	_	_
10-9	1364-1375	association	object[84]|abstract[85]	new[84]|new[85]	coref	15-24[142_85]
10-10	1376-1380	with	object[84]|abstract[85]	new[84]|new[85]	_	_
10-11	1381-1384	MSC	object[84]|abstract[85]|abstract|abstract[88]	new[84]|new[85]|giv|new[88]	coref|coref|coref|coref	11-4|11-25[100_88]|11-4|11-25[100_88]
10-12	1385-1388	and	object[84]|abstract[85]|abstract[88]	new[84]|new[85]|new[88]	_	_
10-13	1389-1395	growth	object[84]|abstract[85]|abstract|abstract[88]	new[84]|new[85]|new|new[88]	coref	21-30
10-14	1396-1403	factors	object[84]|abstract[85]|abstract[88]	new[84]|new[85]|new[88]	_	_
10-15	1404-1405	,	_	_	_	_
10-16	1406-1412	having	_	_	_	_
10-17	1413-1425	requirements	abstract[89]	new[89]	_	_
10-18	1426-1428	of	abstract[89]	new[89]	_	_
10-19	1429-1445	biocompatibility	abstract[89]|substance	new[89]|new	_	_
10-20	1446-1447	,	abstract[89]	new[89]	_	_
10-21	1448-1462	osteoinductive	abstract[89]|abstract[91]	new[89]|new[91]	ana	11-8[0_91]
10-22	1463-1466	and	abstract[89]|abstract[91]	new[89]|new[91]	_	_
10-23	1467-1482	osteoconductive	abstract[89]|abstract[91]	new[89]|new[91]	_	_
10-24	1483-1493	properties	abstract[89]|abstract[91]	new[89]|new[91]	_	_
10-25	1494-1495	,	_	_	_	_
10-26	1496-1499	are	_	_	_	_
10-27	1500-1512	investigated	_	_	_	_
10-28	1513-1515	to	_	_	_	_
10-29	1516-1523	improve	_	_	_	_
10-30	1524-1528	bone	object|abstract[93]	giv|new[93]	coref|coref	13-10|13-10
10-31	1529-1535	repair	abstract[93]	new[93]	_	_
10-32	1536-1537	.	_	_	_	_

#Text=The use of MSC is attractive since they can be harvested from the host with minimal morbidity , they can be modified to secrete osteoinductive factors and implanted on an osteoconductive scaffold , to obtain the three key components leading to osteogenesis .
11-1	1538-1541	The	abstract[94]	new[94]	coref	29-14[296_94]
11-2	1542-1545	use	abstract[94]	new[94]	_	_
11-3	1546-1548	of	abstract[94]	new[94]	_	_
11-4	1549-1552	MSC	abstract[94]|object	new[94]|giv	coref	17-6
11-5	1553-1555	is	_	_	_	_
11-6	1556-1566	attractive	_	_	_	_
11-7	1567-1572	since	_	_	_	_
11-8	1573-1577	they	abstract	giv	ana	11-19
11-9	1578-1581	can	_	_	_	_
11-10	1582-1584	be	_	_	_	_
11-11	1585-1594	harvested	_	_	_	_
11-12	1595-1599	from	_	_	_	_
11-13	1600-1603	the	person[97]	new[97]	_	_
11-14	1604-1608	host	person[97]	new[97]	_	_
11-15	1609-1613	with	person[97]	new[97]	_	_
11-16	1614-1621	minimal	person[97]|event[98]	new[97]|giv[98]	coref	27-3[282_98]
11-17	1622-1631	morbidity	person[97]|event[98]	new[97]|giv[98]	_	_
11-18	1632-1633	,	_	_	_	_
11-19	1634-1638	they	abstract	giv	coref	28-17[290_0]
11-20	1639-1642	can	_	_	_	_
11-21	1643-1645	be	_	_	_	_
11-22	1646-1654	modified	_	_	_	_
11-23	1655-1657	to	_	_	_	_
11-24	1658-1665	secrete	_	_	_	_
11-25	1666-1680	osteoinductive	abstract[100]	giv[100]	coref	21-18[218_100]
11-26	1681-1688	factors	abstract[100]	giv[100]	_	_
11-27	1689-1692	and	_	_	_	_
11-28	1693-1702	implanted	_	_	_	_
11-29	1703-1705	on	_	_	_	_
11-30	1706-1708	an	object[101]	new[101]	_	_
11-31	1709-1724	osteoconductive	object[101]	new[101]	_	_
11-32	1725-1733	scaffold	object[101]	new[101]	_	_
11-33	1734-1735	,	_	_	_	_
11-34	1736-1738	to	_	_	_	_
11-35	1739-1745	obtain	_	_	_	_
11-36	1746-1749	the	abstract[102]	new[102]	_	_
11-37	1750-1755	three	abstract[102]	new[102]	_	_
11-38	1756-1759	key	abstract[102]	new[102]	_	_
11-39	1760-1770	components	abstract[102]	new[102]	_	_
11-40	1771-1778	leading	_	_	_	_
11-41	1779-1781	to	_	_	_	_
11-42	1782-1794	osteogenesis	abstract	new	_	_
11-43	1795-1796	.	_	_	_	_

#Text=hMSC have been found in several adult tissues , including the synovial membrane , the adipose tissue , the dental pulp tissue , or in perinatal tissues ( umbilical cord blood and umbilical cord tissue ) .
12-1	1797-1801	hMSC	substance	new	_	_
12-2	1802-1806	have	_	_	_	_
12-3	1807-1811	been	_	_	_	_
12-4	1812-1817	found	_	_	_	_
12-5	1818-1820	in	_	_	_	_
12-6	1821-1828	several	object[105]	new[105]	_	_
12-7	1829-1834	adult	object[105]	new[105]	_	_
12-8	1835-1842	tissues	object[105]	new[105]	_	_
12-9	1843-1844	,	object[105]	new[105]	_	_
12-10	1845-1854	including	object[105]	new[105]	_	_
12-11	1855-1858	the	object[105]|object[107]	new[105]|new[107]	_	_
12-12	1859-1867	synovial	object[105]|abstract|object[107]	new[105]|new|new[107]	_	_
12-13	1868-1876	membrane	object[105]|object[107]	new[105]|new[107]	_	_
12-14	1877-1878	,	object[105]	new[105]	_	_
12-15	1879-1882	the	object[105]|object[109]	new[105]|giv[109]	coref	12-19[111_109]
12-16	1883-1890	adipose	object[105]|abstract|object[109]	new[105]|new|giv[109]	_	_
12-17	1891-1897	tissue	object[105]|object[109]	new[105]|giv[109]	_	_
12-18	1898-1899	,	object[105]	new[105]	_	_
12-19	1900-1903	the	object[105]|object[111]	new[105]|giv[111]	coref	22-27[0_111]
12-20	1904-1910	dental	object[105]|object[111]	new[105]|giv[111]	_	_
12-21	1911-1915	pulp	object[105]|abstract|object[111]	new[105]|new|giv[111]	_	_
12-22	1916-1922	tissue	object[105]|object[111]	new[105]|giv[111]	_	_
12-23	1923-1924	,	object[105]	new[105]	_	_
12-24	1925-1927	or	object[105]	new[105]	_	_
12-25	1928-1930	in	object[105]	new[105]	_	_
12-26	1931-1940	perinatal	object[105]|object[112]	new[105]|new[112]	appos	12-29[115_112]
12-27	1941-1948	tissues	object[105]|object[112]	new[105]|new[112]	_	_
12-28	1949-1950	(	_	_	_	_
12-29	1951-1960	umbilical	substance[114]|object[115]	new[114]|giv[115]	_	_
12-30	1961-1965	cord	object|substance[114]|object[115]	new|new[114]|giv[115]	coref	12-34
12-31	1966-1971	blood	substance[114]|object[115]	new[114]|giv[115]	_	_
12-32	1972-1975	and	object[115]	giv[115]	_	_
12-33	1976-1985	umbilical	object[115]	giv[115]	_	_
12-34	1986-1990	cord	object[115]|object	giv[115]|giv	_	_
12-35	1991-1997	tissue	object[115]	giv[115]	_	_
12-36	1998-1999	)	_	_	_	_
12-37	2000-2001	.	_	_	_	_

#Text=All these cells are suited to therapeutic applications for bone regeneration , by means of two different ways of autologous cells transplantation : ( 1 ) cell therapies without expansion in culture ( one-step procedure ) and ( 2 ) cell therapies with ex vivo expansion .
13-1	2002-2005	All	object[117]	new[117]	coref	13-21[0_117]
13-2	2006-2011	these	object[117]	new[117]	_	_
13-3	2012-2017	cells	object[117]	new[117]	_	_
13-4	2018-2021	are	_	_	_	_
13-5	2022-2028	suited	_	_	_	_
13-6	2029-2031	to	_	_	_	_
13-7	2032-2043	therapeutic	abstract[118]	new[118]	_	_
13-8	2044-2056	applications	abstract[118]	new[118]	_	_
13-9	2057-2060	for	abstract[118]	new[118]	_	_
13-10	2061-2065	bone	abstract[118]|object|abstract[120]	new[118]|giv|giv[120]	coref|coref|coref|coref	15-15[138_0]|20-27[200_120]|15-15[138_0]|20-27[200_120]
13-11	2066-2078	regeneration	abstract[118]|abstract[120]	new[118]|giv[120]	_	_
13-12	2079-2080	,	abstract[118]	new[118]	_	_
13-13	2081-2083	by	abstract[118]	new[118]	_	_
13-14	2084-2089	means	abstract[118]	new[118]	_	_
13-15	2090-2092	of	abstract[118]	new[118]	_	_
13-16	2093-2096	two	abstract[118]|abstract[121]	new[118]|new[121]	_	_
13-17	2097-2106	different	abstract[118]|abstract[121]	new[118]|new[121]	_	_
13-18	2107-2111	ways	abstract[118]|abstract[121]	new[118]|new[121]	_	_
13-19	2112-2114	of	abstract[118]|abstract[121]	new[118]|new[121]	_	_
13-20	2115-2125	autologous	abstract[118]|abstract[121]|event[123]	new[118]|new[121]|new[123]	coref	17-8[160_123]
13-21	2126-2131	cells	abstract[118]|abstract[121]|object|event[123]	new[118]|new[121]|giv|new[123]	coref	14-6
13-22	2132-2147	transplantation	abstract[118]|abstract[121]|event[123]	new[118]|new[121]|new[123]	_	_
13-23	2148-2149	:	_	_	_	_
13-24	2150-2151	(	_	_	_	_
13-25	2152-2153	1	_	_	_	_
13-26	2154-2155	)	_	_	_	_
13-27	2156-2160	cell	place|person[125]	new|new[125]	coref|coref	13-41|13-41
13-28	2161-2170	therapies	person[125]	new[125]	_	_
13-29	2171-2178	without	person[125]	new[125]	_	_
13-30	2179-2188	expansion	person[125]|abstract[126]	new[125]|new[126]	coref	13-44[131_126]
13-31	2189-2191	in	person[125]|abstract[126]	new[125]|new[126]	_	_
13-32	2192-2199	culture	person[125]|abstract[126]|abstract	new[125]|new[126]|new	appos	13-34[128_0]
13-33	2200-2201	(	_	_	_	_
13-34	2202-2210	one-step	abstract[128]	giv[128]	coref	19-13[0_128]
13-35	2211-2220	procedure	abstract[128]	giv[128]	_	_
13-36	2221-2222	)	_	_	_	_
13-37	2223-2226	and	_	_	_	_
13-38	2227-2228	(	abstract[130]	new[130]	_	_
13-39	2229-2230	2	abstract[130]	new[130]	_	_
13-40	2231-2232	)	abstract[130]	new[130]	_	_
13-41	2233-2237	cell	place|abstract[130]	giv|new[130]	coref	17-10
13-42	2238-2247	therapies	abstract[130]	new[130]	_	_
13-43	2248-2252	with	abstract[130]	new[130]	_	_
13-44	2253-2255	ex	abstract[130]|abstract[131]	new[130]|giv[131]	coref	17-13[161_131]
13-45	2256-2260	vivo	abstract[130]|abstract[131]	new[130]|giv[131]	_	_
13-46	2261-2270	expansion	abstract[130]|abstract[131]	new[130]|giv[131]	_	_
13-47	2271-2272	.	_	_	_	_

#Text=In the first case , cells are harvested during surgery .
14-1	2273-2275	In	_	_	_	_
14-2	2276-2279	the	event[132]	giv[132]	_	_
14-3	2280-2285	first	event[132]	giv[132]	_	_
14-4	2286-2290	case	event[132]	giv[132]	_	_
14-5	2291-2292	,	_	_	_	_
14-6	2293-2298	cells	object	giv	coref	21-6[212_0]
14-7	2299-2302	are	_	_	_	_
14-8	2303-2312	harvested	_	_	_	_
14-9	2313-2319	during	_	_	_	_
14-10	2320-2327	surgery	event	new	coref	29-32[304_0]
14-11	2328-2329	.	_	_	_	_

#Text=In 2010 , Jagër et al. , successfully treated more than 100 patients with local bone healing disorders using a biomaterial composite in association with BM aspiration concentrate .
15-1	2330-2332	In	_	_	_	_
15-2	2333-2337	2010	time	new	_	_
15-3	2338-2339	,	_	_	_	_
15-4	2340-2345	Jagër	person	new	_	_
15-5	2346-2348	et	_	_	_	_
15-6	2349-2352	al.	_	_	_	_
15-7	2353-2354	,	_	_	_	_
15-8	2355-2367	successfully	_	_	_	_
15-9	2368-2375	treated	_	_	_	_
15-10	2376-2380	more	_	_	_	_
15-11	2381-2385	than	_	_	_	_
15-12	2386-2389	100	person[137]	new[137]	ana	16-1[0_137]
15-13	2390-2398	patients	person[137]	new[137]	_	_
15-14	2399-2403	with	person[137]	new[137]	_	_
15-15	2404-2409	local	person[137]|object[138]	new[137]|giv[138]	coref	16-13[151_138]
15-16	2410-2414	bone	person[137]|object[138]	new[137]|giv[138]	_	_
15-17	2415-2422	healing	_	_	_	_
15-18	2423-2432	disorders	abstract	new	_	_
15-19	2433-2438	using	_	_	_	_
15-20	2439-2440	a	object[141]	new[141]	_	_
15-21	2441-2452	biomaterial	organization|object[141]	new|new[141]	coref	18-27[174_0]
15-22	2453-2462	composite	object[141]	new[141]	_	_
15-23	2463-2465	in	_	_	_	_
15-24	2466-2477	association	abstract[142]	giv[142]	_	_
15-25	2478-2482	with	abstract[142]	giv[142]	_	_
15-26	2483-2485	BM	abstract[142]|substance|substance[145]	giv[142]|new|new[145]	coref|coref|coref|coref	16-7|16-7[149_145]|16-7|16-7[149_145]
15-27	2486-2496	aspiration	abstract[142]|abstract|substance[145]	giv[142]|new|new[145]	_	_
15-28	2497-2508	concentrate	abstract[142]|substance[145]	giv[142]|new[145]	_	_
15-29	2509-2510	.	_	_	_	_

#Text=They observed that the use of BM concentrate reduced the harvest of autogenous bone by 50 % without negative effects on bone healing .
16-1	2511-2515	They	person	giv	_	_
16-2	2516-2524	observed	_	_	_	_
16-3	2525-2529	that	_	_	_	_
16-4	2530-2533	the	abstract[147]	new[147]	_	_
16-5	2534-2537	use	abstract[147]	new[147]	_	_
16-6	2538-2540	of	abstract[147]	new[147]	_	_
16-7	2541-2543	BM	abstract[147]|substance|substance[149]	new[147]|giv|giv[149]	coref|coref|coref|coref	18-13|20-21[198_149]|18-13|20-21[198_149]
16-8	2544-2555	concentrate	abstract[147]|substance[149]	new[147]|giv[149]	_	_
16-9	2556-2563	reduced	_	_	_	_
16-10	2564-2567	the	event[150]	new[150]	_	_
16-11	2568-2575	harvest	event[150]	new[150]	_	_
16-12	2576-2578	of	event[150]	new[150]	_	_
16-13	2579-2589	autogenous	event[150]|object[151]	new[150]|giv[151]	coref	16-22[0_151]
16-14	2590-2594	bone	event[150]|object[151]	new[150]|giv[151]	_	_
16-15	2595-2597	by	_	_	_	_
16-16	2598-2600	50	quantity[152]	new[152]	_	_
16-17	2601-2602	%	quantity[152]	new[152]	_	_
16-18	2603-2610	without	_	_	_	_
16-19	2611-2619	negative	abstract[153]	new[153]	_	_
16-20	2620-2627	effects	abstract[153]	new[153]	_	_
16-21	2628-2630	on	abstract[153]	new[153]	_	_
16-22	2631-2635	bone	abstract[153]|object|abstract[155]	new[153]|giv|giv[155]	coref|coref|coref|coref	21-22|22-26[244_155]|21-22|22-26[244_155]
16-23	2636-2643	healing	abstract[153]|abstract[155]	new[153]|giv[155]	_	_
16-24	2644-2645	.	_	_	_	_

#Text=The second clinical application of MSC includes the autologous cell transplantation after ex-vivo expansion .
17-1	2646-2649	The	abstract[156]	new[156]	coref	19-5[180_156]
17-2	2650-2656	second	abstract[156]	new[156]	_	_
17-3	2657-2665	clinical	abstract[156]	new[156]	_	_
17-4	2666-2677	application	abstract[156]	new[156]	_	_
17-5	2678-2680	of	abstract[156]	new[156]	_	_
17-6	2681-2684	MSC	abstract[156]|abstract	new[156]|giv	coref	21-4
17-7	2685-2693	includes	_	_	_	_
17-8	2694-2697	the	event[160]	giv[160]	_	_
17-9	2698-2708	autologous	person|event[160]	new|giv[160]	coref	34-5[328_0]
17-10	2709-2713	cell	place|event[160]	giv|giv[160]	coref	18-10
17-11	2714-2729	transplantation	event[160]	giv[160]	_	_
17-12	2730-2735	after	_	_	_	_
17-13	2736-2743	ex-vivo	abstract[161]	giv[161]	_	_
17-14	2744-2753	expansion	abstract[161]	giv[161]	_	_
17-15	2754-2755	.	_	_	_	_

#Text=In 2007 , Nöth et al. , used a cell population from BM aspirate cultured over 12 days under GMP conditions and transplanted them autologously with a tricalcium phosphate biomaterial for the treatment of femoral head necrosis .
18-1	2756-2758	In	_	_	_	_
18-2	2759-2763	2007	time	new	_	_
18-3	2764-2765	,	_	_	_	_
18-4	2766-2770	Nöth	person	new	_	_
18-5	2771-2773	et	_	_	_	_
18-6	2774-2777	al.	_	_	_	_
18-7	2778-2779	,	_	_	_	_
18-8	2780-2784	used	_	_	_	_
18-9	2785-2786	a	abstract[165]	new[165]	_	_
18-10	2787-2791	cell	place|abstract[165]	giv|new[165]	coref	19-24
18-11	2792-2802	population	abstract[165]	new[165]	_	_
18-12	2803-2807	from	_	_	_	_
18-13	2808-2810	BM	abstract|time[167]	giv|new[167]	coref|coref|coref|coref	20-15|20-15[195_167]|20-15|20-15[195_167]
18-14	2811-2819	aspirate	time[167]	new[167]	_	_
18-15	2820-2828	cultured	_	_	_	_
18-16	2829-2833	over	time[168]	new[168]	_	_
18-17	2834-2836	12	time[168]	new[168]	_	_
18-18	2837-2841	days	time[168]	new[168]	_	_
18-19	2842-2847	under	_	_	_	_
18-20	2848-2851	GMP	place|abstract[170]	new|new[170]	ana|coref|ana|coref	18-24[0_170]|20-44|18-24[0_170]|20-44
18-21	2852-2862	conditions	abstract[170]	new[170]	_	_
18-22	2863-2866	and	_	_	_	_
18-23	2867-2879	transplanted	_	_	_	_
18-24	2880-2884	them	abstract	giv	_	_
18-25	2885-2897	autologously	_	_	_	_
18-26	2898-2902	with	_	_	_	_
18-27	2903-2904	a	organization[174]	giv[174]	_	_
18-28	2905-2915	tricalcium	place|organization[174]	new|giv[174]	_	_
18-29	2916-2925	phosphate	person|organization[174]	new|giv[174]	_	_
18-30	2926-2937	biomaterial	organization[174]	giv[174]	_	_
18-31	2938-2941	for	_	_	_	_
18-32	2942-2945	the	abstract[175]	new[175]	coref	23-19[253_175]
18-33	2946-2955	treatment	abstract[175]	new[175]	_	_
18-34	2956-2958	of	abstract[175]	new[175]	_	_
18-35	2959-2966	femoral	abstract[175]|abstract|object[178]	new[175]|new|new[178]	_	_
18-36	2967-2971	head	abstract[175]|object|object[178]	new[175]|new|new[178]	_	_
18-37	2972-2980	necrosis	abstract[175]|object[178]	new[175]|new[178]	_	_
18-38	2981-2982	.	_	_	_	_

#Text=The main limitations for clinical application are the sterility technique , long culture time , high cost , and the mixture of human cell culture medium with fetal bovine serum .
19-1	2983-2986	The	abstract[179]	giv[179]	coref	19-8[182_179]
19-2	2987-2991	main	abstract[179]	giv[179]	_	_
19-3	2992-3003	limitations	abstract[179]	giv[179]	_	_
19-4	3004-3007	for	abstract[179]	giv[179]	_	_
19-5	3008-3016	clinical	abstract[179]|abstract[180]	giv[179]|giv[180]	coref	32-19[321_180]
19-6	3017-3028	application	abstract[179]|abstract[180]	giv[179]|giv[180]	_	_
19-7	3029-3032	are	_	_	_	_
19-8	3033-3036	the	abstract[182]	giv[182]	_	_
19-9	3037-3046	sterility	abstract|abstract[182]	new|giv[182]	_	_
19-10	3047-3056	technique	abstract[182]	giv[182]	_	_
19-11	3057-3058	,	abstract[182]	giv[182]	_	_
19-12	3059-3063	long	abstract[182]|time[184]	giv[182]|new[184]	_	_
19-13	3064-3071	culture	abstract[182]|abstract|time[184]	giv[182]|giv|new[184]	coref	19-23[188_0]
19-14	3072-3076	time	abstract[182]|time[184]	giv[182]|new[184]	_	_
19-15	3077-3078	,	abstract[182]	giv[182]	_	_
19-16	3079-3083	high	abstract[182]|abstract[185]	giv[182]|new[185]	_	_
19-17	3084-3088	cost	abstract[182]|abstract[185]	giv[182]|new[185]	_	_
19-18	3089-3090	,	abstract[182]	giv[182]	_	_
19-19	3091-3094	and	abstract[182]	giv[182]	_	_
19-20	3095-3098	the	abstract[182]|abstract[186]	giv[182]|new[186]	_	_
19-21	3099-3106	mixture	abstract[182]|abstract[186]	giv[182]|new[186]	_	_
19-22	3107-3109	of	abstract[182]|abstract[186]	giv[182]|new[186]	_	_
19-23	3110-3115	human	abstract[182]|abstract[186]|abstract[188]	giv[182]|new[186]|giv[188]	coref	20-30[201_188]
19-24	3116-3120	cell	abstract[182]|abstract[186]|place|abstract[188]	giv[182]|new[186]|giv|giv[188]	_	_
19-25	3121-3128	culture	abstract[182]|abstract[186]|abstract[188]	giv[182]|new[186]|giv[188]	_	_
19-26	3129-3135	medium	abstract[182]|abstract[186]|abstract[188]	giv[182]|new[186]|giv[188]	_	_
19-27	3136-3140	with	_	_	_	_
19-28	3141-3146	fetal	substance[189]	new[189]	_	_
19-29	3147-3153	bovine	substance[189]	new[189]	_	_
19-30	3154-3159	serum	substance[189]	new[189]	_	_
19-31	3160-3161	.	_	_	_	_

#Text=Thus , recently , orthopedic researchers focused their attention on the clinical use of BM aspirate ( BMA ) and BM concentrate ( BMC ) for musculoskeletal regeneration with a “ one-step ” procedure , avoiding the need of additional laboratory stages and GMP facility , thus reducing costs and risks .
20-1	3162-3166	Thus	_	_	_	_
20-2	3167-3168	,	_	_	_	_
20-3	3169-3177	recently	_	_	_	_
20-4	3178-3179	,	_	_	_	_
20-5	3180-3190	orthopedic	person[190]	new[190]	ana	20-8[0_190]
20-6	3191-3202	researchers	person[190]	new[190]	_	_
20-7	3203-3210	focused	_	_	_	_
20-8	3211-3216	their	person|abstract[192]	giv|new[192]	coref|coref	23-3[247_192]|23-3[247_192]
20-9	3217-3226	attention	abstract[192]	new[192]	_	_
20-10	3227-3229	on	_	_	_	_
20-11	3230-3233	the	abstract[193]	new[193]	_	_
20-12	3234-3242	clinical	abstract[193]	new[193]	_	_
20-13	3243-3246	use	abstract[193]	new[193]	_	_
20-14	3247-3249	of	abstract[193]	new[193]	_	_
20-15	3250-3252	BM	abstract[193]|abstract|object[195]	new[193]|giv|giv[195]	appos|coref|appos|coref	20-18[0_195]|20-21|20-18[0_195]|20-21
20-16	3253-3261	aspirate	abstract[193]|object[195]	new[193]|giv[195]	_	_
20-17	3262-3263	(	_	_	_	_
20-18	3264-3267	BMA	object	giv	_	_
20-19	3268-3269	)	_	_	_	_
20-20	3270-3273	and	_	_	_	_
20-21	3274-3276	BM	substance|substance[198]	giv|giv[198]	coref|coref	34-5[329_0]|34-5[329_0]
20-22	3277-3288	concentrate	substance[198]	giv[198]	_	_
20-23	3289-3290	(	_	_	_	_
20-24	3291-3294	BMC	object	new	_	_
20-25	3295-3296	)	_	_	_	_
20-26	3297-3300	for	_	_	_	_
20-27	3301-3316	musculoskeletal	abstract[200]	giv[200]	coref	28-20[292_200]
20-28	3317-3329	regeneration	abstract[200]	giv[200]	_	_
20-29	3330-3334	with	abstract[200]	giv[200]	_	_
20-30	3335-3336	a	abstract[200]|abstract[201]	giv[200]|giv[201]	_	_
20-31	3337-3338	“	abstract[200]|abstract[201]	giv[200]|giv[201]	_	_
20-32	3339-3347	one-step	abstract[200]|abstract[201]	giv[200]|giv[201]	_	_
20-33	3348-3349	”	abstract[200]|abstract[201]	giv[200]|giv[201]	_	_
20-34	3350-3359	procedure	abstract[200]|abstract[201]	giv[200]|giv[201]	_	_
20-35	3360-3361	,	_	_	_	_
20-36	3362-3370	avoiding	_	_	_	_
20-37	3371-3374	the	abstract[202]	giv[202]	_	_
20-38	3375-3379	need	abstract[202]	giv[202]	_	_
20-39	3380-3382	of	abstract[202]	giv[202]	_	_
20-40	3383-3393	additional	abstract[202]|abstract[204]	giv[202]|new[204]	_	_
20-41	3394-3404	laboratory	abstract[202]|place|abstract[204]	giv[202]|new|new[204]	_	_
20-42	3405-3411	stages	abstract[202]|abstract[204]	giv[202]|new[204]	_	_
20-43	3412-3415	and	abstract[202]	giv[202]	_	_
20-44	3416-3419	GMP	abstract[202]|place|abstract[206]	giv[202]|giv|new[206]	_	_
20-45	3420-3428	facility	abstract[202]|abstract[206]	giv[202]|new[206]	_	_
20-46	3429-3430	,	_	_	_	_
20-47	3431-3435	thus	_	_	_	_
20-48	3436-3444	reducing	_	_	_	_
20-49	3445-3450	costs	abstract[207]	giv[207]	_	_
20-50	3451-3454	and	abstract[207]	giv[207]	_	_
20-51	3455-3460	risks	abstract[207]|abstract	giv[207]|giv	_	_
20-52	3461-3462	.	_	_	_	_

#Text=Bone marrow contains MSC , hematopoietic stem cells , endothelial progenitor cells , other progenitor cells and growth factors , including bone morphogenetic proteins ( BMP ) , platelet-derived growth factor ( PDGF ) , transforming growth factor-β ( TGF-β ) , vascular endothelial growth factor ( VEGF ) , interleukin-8 ( IL-8 ) , and IL-1 receptor antagonist .
21-1	3463-3467	Bone	person|object[210]	giv|new[210]	_	_
21-2	3468-3474	marrow	object[210]	new[210]	_	_
21-3	3475-3483	contains	_	_	_	_
21-4	3484-3487	MSC	place	giv	coref	23-9[250_0]
21-5	3488-3489	,	_	_	_	_
21-6	3490-3503	hematopoietic	object[212]	giv[212]	coref	21-10[215_212]
21-7	3504-3508	stem	object[212]	giv[212]	_	_
21-8	3509-3514	cells	object[212]	giv[212]	_	_
21-9	3515-3516	,	_	_	_	_
21-10	3517-3528	endothelial	object|object[215]	new|giv[215]	coref|coref|coref|coref	21-14[217_215]|21-44|21-14[217_215]|21-44
21-11	3529-3539	progenitor	object|object[215]	new|giv[215]	coref	21-15
21-12	3540-3545	cells	object[215]	giv[215]	_	_
21-13	3546-3547	,	_	_	_	_
21-14	3548-3553	other	object[217]	giv[217]	coref	22-10[237_217]
21-15	3554-3564	progenitor	object|object[217]	giv|giv[217]	_	_
21-16	3565-3570	cells	object[217]	giv[217]	_	_
21-17	3571-3574	and	_	_	_	_
21-18	3575-3581	growth	abstract[218]	giv[218]	coref	22-12[238_218]
21-19	3582-3589	factors	abstract[218]	giv[218]	_	_
21-20	3590-3591	,	_	_	_	_
21-21	3592-3601	including	_	_	_	_
21-22	3602-3606	bone	object|substance[220]	giv|new[220]	coref|coref	22-22|22-22
21-23	3607-3620	morphogenetic	substance[220]	new[220]	_	_
21-24	3621-3629	proteins	substance[220]	new[220]	_	_
21-25	3630-3631	(	_	_	_	_
21-26	3632-3635	BMP	object	new	_	_
21-27	3636-3637	)	_	_	_	_
21-28	3638-3639	,	_	_	_	_
21-29	3640-3656	platelet-derived	abstract[223]	new[223]	coref	21-43[230_223]
21-30	3657-3663	growth	abstract|abstract[223]	giv|new[223]	coref	21-37
21-31	3664-3670	factor	abstract[223]	new[223]	_	_
21-32	3671-3672	(	_	_	_	_
21-33	3673-3677	PDGF	object	new	_	_
21-34	3678-3679	)	_	_	_	_
21-35	3680-3681	,	_	_	_	_
21-36	3682-3694	transforming	_	_	_	_
21-37	3695-3701	growth	abstract|abstract[226]	giv|new[226]	appos|coref|appos|coref	21-40[0_226]|21-45|21-40[0_226]|21-45
21-38	3702-3710	factor-β	abstract[226]	new[226]	_	_
21-39	3711-3712	(	_	_	_	_
21-40	3713-3718	TGF-β	abstract	giv	_	_
21-41	3719-3720	)	_	_	_	_
21-42	3721-3722	,	_	_	_	_
21-43	3723-3731	vascular	abstract[230]	giv[230]	appos	21-48[0_230]
21-44	3732-3743	endothelial	abstract|abstract[230]	giv|giv[230]	_	_
21-45	3744-3750	growth	abstract|abstract[230]	giv|giv[230]	_	_
21-46	3751-3757	factor	abstract[230]	giv[230]	_	_
21-47	3758-3759	(	_	_	_	_
21-48	3760-3764	VEGF	abstract	giv	_	_
21-49	3765-3766	)	_	_	_	_
21-50	3767-3768	,	_	_	_	_
21-51	3769-3782	interleukin-8	abstract	new	appos	21-53
21-52	3783-3784	(	_	_	_	_
21-53	3785-3789	IL-8	abstract	giv	ana	22-1
21-54	3790-3791	)	_	_	_	_
21-55	3792-3793	,	_	_	_	_
21-56	3794-3797	and	_	_	_	_
21-57	3798-3802	IL-1	object[234]	new[234]	_	_
21-58	3803-3811	receptor	object[234]|substance	new[234]|new	_	_
21-59	3812-3822	antagonist	object[234]	new[234]	_	_
21-60	3823-3824	.	_	_	_	_

#Text=It has been identified as an excellent source of cells and growth factors and it has been used with success for bone , cartilage and soft tissue healing .
22-1	3825-3827	It	abstract	giv	ana	22-15
22-2	3828-3831	has	_	_	_	_
22-3	3832-3836	been	_	_	_	_
22-4	3837-3847	identified	_	_	_	_
22-5	3848-3850	as	_	_	_	_
22-6	3851-3853	an	_	_	_	_
22-7	3854-3863	excellent	_	_	_	_
22-8	3864-3870	source	_	_	_	_
22-9	3871-3873	of	_	_	_	_
22-10	3874-3879	cells	object[237]	giv[237]	coref	33-9[324_237]
22-11	3880-3883	and	object[237]	giv[237]	_	_
22-12	3884-3890	growth	object[237]|abstract[238]	giv[237]|giv[238]	_	_
22-13	3891-3898	factors	object[237]|abstract[238]	giv[237]|giv[238]	_	_
22-14	3899-3902	and	_	_	_	_
22-15	3903-3905	it	abstract	giv	_	_
22-16	3906-3909	has	_	_	_	_
22-17	3910-3914	been	_	_	_	_
22-18	3915-3919	used	_	_	_	_
22-19	3920-3924	with	_	_	_	_
22-20	3925-3932	success	abstract[240]	new[240]	coref	25-13[0_240]
22-21	3933-3936	for	abstract[240]	new[240]	_	_
22-22	3937-3941	bone	abstract[240]|object	new[240]|giv	_	_
22-23	3942-3943	,	abstract[240]	new[240]	_	_
22-24	3944-3953	cartilage	abstract[240]|object	new[240]|new	_	_
22-25	3954-3957	and	abstract[240]	new[240]	_	_
22-26	3958-3962	soft	abstract[240]|abstract[244]	new[240]|giv[244]	_	_
22-27	3963-3969	tissue	abstract[240]|object|abstract[244]	new[240]|giv|giv[244]	_	_
22-28	3970-3977	healing	abstract[240]|abstract[244]	new[240]|giv[244]	_	_
22-29	3978-3979	.	_	_	_	_

#Text=We focused our attention on the use of BM-derived MSC in spinal fusion surgical procedures , which is the most definitive treatment performed to restore the structural stability of the spinal column in degenerative and oncological spine diseases .
23-1	3980-3982	We	person	acc	ana	23-3
23-2	3983-3990	focused	_	_	_	_
23-3	3991-3994	our	person|abstract[247]	giv|giv[247]	ana|ana	29-1|29-1
23-4	3995-4004	attention	abstract[247]	giv[247]	_	_
23-5	4005-4007	on	_	_	_	_
23-6	4008-4011	the	abstract[248]	new[248]	_	_
23-7	4012-4015	use	abstract[248]	new[248]	_	_
23-8	4016-4018	of	abstract[248]	new[248]	_	_
23-9	4019-4029	BM-derived	abstract[248]|abstract|place[250]	new[248]|new|giv[250]	coref|coref	28-10[0_250]|28-10[0_250]
23-10	4030-4033	MSC	abstract[248]|place[250]	new[248]|giv[250]	_	_
23-11	4034-4036	in	abstract[248]|place[250]	new[248]|giv[250]	_	_
23-12	4037-4043	spinal	abstract[248]|place[250]|abstract[252]	new[248]|giv[250]|new[252]	_	_
23-13	4044-4050	fusion	abstract[248]|place[250]|abstract|abstract[252]	new[248]|giv[250]|new|new[252]	coref	24-9[261_0]
23-14	4051-4059	surgical	abstract[248]|place[250]|abstract[252]	new[248]|giv[250]|new[252]	_	_
23-15	4060-4070	procedures	abstract[248]|place[250]|abstract[252]	new[248]|giv[250]|new[252]	_	_
23-16	4071-4072	,	_	_	_	_
23-17	4073-4078	which	_	_	_	_
23-18	4079-4081	is	_	_	_	_
23-19	4082-4085	the	abstract[253]	giv[253]	_	_
23-20	4086-4090	most	abstract[253]	giv[253]	_	_
23-21	4091-4101	definitive	abstract[253]	giv[253]	_	_
23-22	4102-4111	treatment	abstract[253]	giv[253]	_	_
23-23	4112-4121	performed	_	_	_	_
23-24	4122-4124	to	_	_	_	_
23-25	4125-4132	restore	_	_	_	_
23-26	4133-4136	the	abstract[254]	new[254]	_	_
23-27	4137-4147	structural	abstract[254]	new[254]	_	_
23-28	4148-4157	stability	abstract[254]	new[254]	_	_
23-29	4158-4160	of	abstract[254]	new[254]	_	_
23-30	4161-4164	the	abstract[254]|object[255]	new[254]|new[255]	_	_
23-31	4165-4171	spinal	abstract[254]|object[255]	new[254]|new[255]	_	_
23-32	4172-4178	column	abstract[254]|object[255]	new[254]|new[255]	_	_
23-33	4179-4181	in	abstract[254]|object[255]	new[254]|new[255]	_	_
23-34	4182-4194	degenerative	abstract[254]|object[255]|abstract[257]	new[254]|new[255]|giv[257]	_	_
23-35	4195-4198	and	abstract[254]|object[255]|abstract[257]	new[254]|new[255]|giv[257]	_	_
23-36	4199-4210	oncological	abstract[254]|object[255]|abstract[257]	new[254]|new[255]|giv[257]	_	_
23-37	4211-4216	spine	abstract[254]|object[255]|object|abstract[257]	new[254]|new[255]|new|giv[257]	coref	29-32
23-38	4217-4225	diseases	abstract[254]|object[255]|abstract[257]	new[254]|new[255]|giv[257]	_	_
23-39	4226-4227	.	_	_	_	_

#Text=Currently , the gold standard stimulus to achieve spinal fusion is autologous bone ( autograft ) , which is commonly harvested from the iliac crest or obtained from the surgical site ( local bone ) .
24-1	4228-4237	Currently	_	_	_	_
24-2	4238-4239	,	_	_	_	_
24-3	4240-4243	the	object[259]	new[259]	coref	24-12[262_259]
24-4	4244-4248	gold	substance|object[259]	new|new[259]	_	_
24-5	4249-4257	standard	object[259]	new[259]	_	_
24-6	4258-4266	stimulus	object[259]	new[259]	_	_
24-7	4267-4269	to	_	_	_	_
24-8	4270-4277	achieve	_	_	_	_
24-9	4278-4284	spinal	substance|abstract[261]	new|giv[261]	coref|coref|coref|coref	25-16|25-16[273_261]|25-16|25-16[273_261]
24-10	4285-4291	fusion	abstract[261]	giv[261]	_	_
24-11	4292-4294	is	_	_	_	_
24-12	4295-4305	autologous	object[262]	giv[262]	appos	24-15[0_262]
24-13	4306-4310	bone	object[262]	giv[262]	_	_
24-14	4311-4312	(	_	_	_	_
24-15	4313-4322	autograft	object	giv	appos	24-33[267_0]
24-16	4323-4324	)	_	_	_	_
24-17	4325-4326	,	_	_	_	_
24-18	4327-4332	which	_	_	_	_
24-19	4333-4335	is	_	_	_	_
24-20	4336-4344	commonly	_	_	_	_
24-21	4345-4354	harvested	_	_	_	_
24-22	4355-4359	from	_	_	_	_
24-23	4360-4363	the	place[265]	giv[265]	_	_
24-24	4364-4369	iliac	person|place[265]	giv|giv[265]	_	_
24-25	4370-4375	crest	place[265]	giv[265]	_	_
24-26	4376-4378	or	_	_	_	_
24-27	4379-4387	obtained	_	_	_	_
24-28	4388-4392	from	_	_	_	_
24-29	4393-4396	the	place[266]	giv[266]	_	_
24-30	4397-4405	surgical	place[266]	giv[266]	_	_
24-31	4406-4410	site	place[266]	giv[266]	_	_
24-32	4411-4412	(	_	_	_	_
24-33	4413-4418	local	object[267]	giv[267]	coref	25-2[268_267]
24-34	4419-4423	bone	object[267]	giv[267]	_	_
24-35	4424-4425	)	_	_	_	_
24-36	4426-4427	.	_	_	_	_

#Text=As autologous bone possesses osteogenic , osteoinductive and osteoconductive abilities ; the success rate of spinal fusion with autograft is high ( up to 95 % ) .
25-1	4428-4430	As	_	_	_	_
25-2	4431-4441	autologous	object[268]	giv[268]	coref	25-19[0_268]
25-3	4442-4446	bone	object[268]	giv[268]	_	_
25-4	4447-4456	possesses	_	_	_	_
25-5	4457-4467	osteogenic	abstract[269]	new[269]	_	_
25-6	4468-4469	,	abstract[269]	new[269]	_	_
25-7	4470-4484	osteoinductive	abstract[269]	new[269]	_	_
25-8	4485-4488	and	abstract[269]	new[269]	_	_
25-9	4489-4504	osteoconductive	abstract[269]	new[269]	_	_
25-10	4505-4514	abilities	abstract[269]	new[269]	_	_
25-11	4515-4516	;	_	_	_	_
25-12	4517-4520	the	abstract[271]	new[271]	_	_
25-13	4521-4528	success	abstract|abstract[271]	giv|new[271]	_	_
25-14	4529-4533	rate	abstract[271]	new[271]	_	_
25-15	4534-4536	of	abstract[271]	new[271]	_	_
25-16	4537-4543	spinal	abstract[271]|substance|abstract[273]	new[271]|giv|giv[273]	coref|coref|coref|coref	28-7|28-7[287_273]|28-7|28-7[287_273]
25-17	4544-4550	fusion	abstract[271]|abstract[273]	new[271]|giv[273]	_	_
25-18	4551-4555	with	abstract[271]|abstract[273]	new[271]|giv[273]	_	_
25-19	4556-4565	autograft	abstract[271]|abstract[273]|abstract	new[271]|giv[273]|giv	coref	26-3
25-20	4566-4568	is	_	_	_	_
25-21	4569-4573	high	_	_	_	_
25-22	4574-4575	(	_	_	_	_
25-23	4576-4578	up	_	_	_	_
25-24	4579-4581	to	_	_	_	_
25-25	4582-4584	95	quantity[275]	new[275]	_	_
25-26	4585-4586	%	quantity[275]	new[275]	_	_
25-27	4587-4588	)	_	_	_	_
25-28	4589-4590	.	_	_	_	_

#Text=However , autograft material is limited in quantity and its quality varies depending on the patient .
26-1	4591-4598	However	_	_	_	_
26-2	4599-4600	,	_	_	_	_
26-3	4601-4610	autograft	object|object[277]	giv|new[277]	coref|coref	27-8|27-8
26-4	4611-4619	material	object[277]	new[277]	_	_
26-5	4620-4622	is	_	_	_	_
26-6	4623-4630	limited	_	_	_	_
26-7	4631-4633	in	_	_	_	_
26-8	4634-4642	quantity	quantity	new	ana	26-10
26-9	4643-4646	and	_	_	_	_
26-10	4647-4650	its	quantity|abstract[280]	giv|new[280]	_	_
26-11	4651-4658	quality	abstract[280]	new[280]	_	_
26-12	4659-4665	varies	_	_	_	_
26-13	4666-4675	depending	_	_	_	_
26-14	4676-4678	on	_	_	_	_
26-15	4679-4682	the	person[281]	new[281]	_	_
26-16	4683-4690	patient	person[281]	new[281]	_	_
26-17	4691-4692	.	_	_	_	_

#Text=Moreover , significant morbidity is associated with bone harvesting , as previously described .
27-1	4693-4701	Moreover	_	_	_	_
27-2	4702-4703	,	_	_	_	_
27-3	4704-4715	significant	event[282]	giv[282]	_	_
27-4	4716-4725	morbidity	event[282]	giv[282]	_	_
27-5	4726-4728	is	_	_	_	_
27-6	4729-4739	associated	_	_	_	_
27-7	4740-4744	with	_	_	_	_
27-8	4745-4749	bone	object|event[284]	giv|new[284]	coref|coref	28-20|28-20
27-9	4750-4760	harvesting	event[284]	new[284]	_	_
27-10	4761-4762	,	_	_	_	_
27-11	4763-4765	as	_	_	_	_
27-12	4766-4776	previously	_	_	_	_
27-13	4777-4786	described	_	_	_	_
27-14	4787-4788	.	_	_	_	_

#Text=Between many alternatives proposed to achieve spinal fusion , MSC are interesting because they can provide osteogenic properties allowing bone regeneration .
28-1	4789-4796	Between	_	_	_	_
28-2	4797-4801	many	abstract[285]	new[285]	ana	28-14[0_285]
28-3	4802-4814	alternatives	abstract[285]	new[285]	_	_
28-4	4815-4823	proposed	_	_	_	_
28-5	4824-4826	to	_	_	_	_
28-6	4827-4834	achieve	_	_	_	_
28-7	4835-4841	spinal	substance|abstract[287]	giv|giv[287]	coref|coref|coref|coref	29-30[0_287]|31-16|29-30[0_287]|31-16
28-8	4842-4848	fusion	abstract[287]	giv[287]	_	_
28-9	4849-4850	,	_	_	_	_
28-10	4851-4854	MSC	object	giv	coref	29-17
28-11	4855-4858	are	_	_	_	_
28-12	4859-4870	interesting	_	_	_	_
28-13	4871-4878	because	_	_	_	_
28-14	4879-4883	they	abstract	giv	_	_
28-15	4884-4887	can	_	_	_	_
28-16	4888-4895	provide	_	_	_	_
28-17	4896-4906	osteogenic	abstract[290]	giv[290]	_	_
28-18	4907-4917	properties	abstract[290]	giv[290]	_	_
28-19	4918-4926	allowing	_	_	_	_
28-20	4927-4931	bone	object|abstract[292]	giv|giv[292]	coref|coref|coref|coref	29-27|29-27[300_292]|29-27|29-27[300_292]
28-21	4932-4944	regeneration	abstract[292]	giv[292]	_	_
28-22	4945-4946	.	_	_	_	_

#Text=We recently published a descriptive systematic literature review in order to understand if the use of MSC may represent a valid strategy to facilitate and accelerate bone regeneration and fusion during spine surgery .
29-1	4947-4949	We	person	giv	ana	30-4
29-2	4950-4958	recently	_	_	_	_
29-3	4959-4968	published	_	_	_	_
29-4	4969-4970	a	abstract[295]	new[295]	coref	30-2[305_295]
29-5	4971-4982	descriptive	abstract[295]	new[295]	_	_
29-6	4983-4993	systematic	abstract[295]	new[295]	_	_
29-7	4994-5004	literature	abstract|abstract[295]	new|new[295]	_	_
29-8	5005-5011	review	abstract[295]	new[295]	_	_
29-9	5012-5014	in	_	_	_	_
29-10	5015-5020	order	_	_	_	_
29-11	5021-5023	to	_	_	_	_
29-12	5024-5034	understand	_	_	_	_
29-13	5035-5037	if	_	_	_	_
29-14	5038-5041	the	abstract[296]	giv[296]	_	_
29-15	5042-5045	use	abstract[296]	giv[296]	_	_
29-16	5046-5048	of	abstract[296]	giv[296]	_	_
29-17	5049-5052	MSC	abstract[296]|event	giv[296]|giv	coref	31-6
29-18	5053-5056	may	_	_	_	_
29-19	5057-5066	represent	_	_	_	_
29-20	5067-5068	a	abstract[298]	new[298]	_	_
29-21	5069-5074	valid	abstract[298]	new[298]	_	_
29-22	5075-5083	strategy	abstract[298]	new[298]	_	_
29-23	5084-5086	to	_	_	_	_
29-24	5087-5097	facilitate	_	_	_	_
29-25	5098-5101	and	_	_	_	_
29-26	5102-5112	accelerate	_	_	_	_
29-27	5113-5117	bone	object|abstract[300]|abstract[301]	giv|giv[300]|giv[301]	_	_
29-28	5118-5130	regeneration	abstract[300]|abstract[301]	giv[300]|giv[301]	_	_
29-29	5131-5134	and	abstract[301]	giv[301]	_	_
29-30	5135-5141	fusion	abstract[301]|abstract	giv[301]|giv	coref	31-16[315_0]
29-31	5142-5148	during	_	_	_	_
29-32	5149-5154	spine	object|event[304]	giv|giv[304]	_	_
29-33	5155-5162	surgery	event[304]	giv[304]	_	_
29-34	5163-5164	.	_	_	_	_

#Text=In this review we selected and analyzed 50 relevant papers , stratified according to preclinical studies and clinical trials .
30-1	5165-5167	In	_	_	_	_
30-2	5168-5172	this	abstract[305]	giv[305]	_	_
30-3	5173-5179	review	abstract[305]	giv[305]	_	_
30-4	5180-5182	we	person	giv	_	_
30-5	5183-5191	selected	_	_	_	_
30-6	5192-5195	and	_	_	_	_
30-7	5196-5204	analyzed	_	_	_	_
30-8	5205-5207	50	object[307]	new[307]	_	_
30-9	5208-5216	relevant	object[307]	new[307]	_	_
30-10	5217-5223	papers	object[307]	new[307]	_	_
30-11	5224-5225	,	_	_	_	_
30-12	5226-5236	stratified	_	_	_	_
30-13	5237-5246	according	_	_	_	_
30-14	5247-5249	to	_	_	_	_
30-15	5250-5261	preclinical	abstract[308]|person[309]	new[308]|new[309]	coref|ana|coref|ana	32-3[316_308]|34-3[0_309]|32-3[316_308]|34-3[0_309]
30-16	5262-5269	studies	abstract[308]|person[309]	new[308]|new[309]	_	_
30-17	5270-5273	and	person[309]	new[309]	_	_
30-18	5274-5282	clinical	person[309]|event[310]	new[309]|new[310]	_	_
30-19	5283-5289	trials	person[309]|event[310]	new[309]|new[310]	_	_
30-20	5290-5291	.	_	_	_	_

#Text=Preclinical published data showed that MSC have the potential to achieve , facilitate and accelerate spinal fusion .
31-1	5292-5303	Preclinical	abstract[311]	new[311]	_	_
31-2	5304-5313	published	abstract[311]	new[311]	_	_
31-3	5314-5318	data	abstract[311]	new[311]	_	_
31-4	5319-5325	showed	_	_	_	_
31-5	5326-5330	that	_	_	_	_
31-6	5331-5334	MSC	object	giv	_	_
31-7	5335-5339	have	_	_	_	_
31-8	5340-5343	the	abstract[313]	new[313]	_	_
31-9	5344-5353	potential	abstract[313]	new[313]	_	_
31-10	5354-5356	to	_	_	_	_
31-11	5357-5364	achieve	_	_	_	_
31-12	5365-5366	,	_	_	_	_
31-13	5367-5377	facilitate	_	_	_	_
31-14	5378-5381	and	_	_	_	_
31-15	5382-5392	accelerate	_	_	_	_
31-16	5393-5399	spinal	substance|abstract[315]	giv|giv[315]	coref|coref|coref|coref	33-12|33-12[326_315]|33-12|33-12[326_315]
31-17	5400-5406	fusion	abstract[315]	giv[315]	_	_
31-18	5407-5408	.	_	_	_	_

#Text=However , preclinical studies on animal models indicated that some barriers remain prior to this therapy translation into the clinical application .
32-1	5409-5416	However	_	_	_	_
32-2	5417-5418	,	_	_	_	_
32-3	5419-5430	preclinical	abstract[316]	giv[316]	coref	33-4[322_316]
32-4	5431-5438	studies	abstract[316]	giv[316]	_	_
32-5	5439-5441	on	abstract[316]	giv[316]	_	_
32-6	5442-5448	animal	abstract[316]|object[317]	giv[316]|new[317]	_	_
32-7	5449-5455	models	abstract[316]|object[317]	giv[316]|new[317]	_	_
32-8	5456-5465	indicated	_	_	_	_
32-9	5466-5470	that	_	_	_	_
32-10	5471-5475	some	abstract[318]	new[318]	_	_
32-11	5476-5484	barriers	abstract[318]	new[318]	_	_
32-12	5485-5491	remain	_	_	_	_
32-13	5492-5497	prior	_	_	_	_
32-14	5498-5500	to	_	_	_	_
32-15	5501-5505	this	abstract[320]	new[320]	_	_
32-16	5506-5513	therapy	abstract|abstract[320]	new|new[320]	_	_
32-17	5514-5525	translation	abstract[320]	new[320]	_	_
32-18	5526-5530	into	abstract[320]	new[320]	_	_
32-19	5531-5534	the	abstract[320]|abstract[321]	new[320]|giv[321]	_	_
32-20	5535-5543	clinical	abstract[320]|abstract[321]	new[320]|giv[321]	_	_
32-21	5544-5555	application	abstract[320]|abstract[321]	new[320]|giv[321]	_	_
32-22	5556-5557	.	_	_	_	_

#Text=So far , few published clinical studies employ stem cells for spinal fusion .
33-1	5558-5560	So	_	_	_	_
33-2	5561-5564	far	_	_	_	_
33-3	5565-5566	,	_	_	_	_
33-4	5567-5570	few	abstract[322]	giv[322]	_	_
33-5	5571-5580	published	abstract[322]	giv[322]	_	_
33-6	5581-5589	clinical	abstract[322]	giv[322]	_	_
33-7	5590-5597	studies	abstract[322]	giv[322]	_	_
33-8	5598-5604	employ	_	_	_	_
33-9	5605-5609	stem	plant|object[324]	new|giv[324]	coref|coref	34-12[330_324]|34-12[330_324]
33-10	5610-5615	cells	object[324]	giv[324]	_	_
33-11	5616-5619	for	object[324]	giv[324]	_	_
33-12	5620-5626	spinal	object[324]|substance|abstract[326]	giv[324]|giv|giv[326]	coref|coref	34-17[0_326]|34-17[0_326]
33-13	5627-5633	fusion	object[324]|abstract[326]	giv[324]|giv[326]	_	_
33-14	5634-5635	.	_	_	_	_

#Text=Most of them used concentrated autologous BM as primary source of stem cells and they showed fusion results ranging from 87 % to 92.3 % in a total of 297 patients .
34-1	5636-5640	Most	_	_	_	_
34-2	5641-5643	of	_	_	_	_
34-3	5644-5648	them	person	giv	ana	34-15
34-4	5649-5653	used	_	_	_	_
34-5	5654-5666	concentrated	person[328]|substance[329]	giv[328]|giv[329]	_	_
34-6	5667-5677	autologous	person[328]|substance[329]	giv[328]|giv[329]	_	_
34-7	5678-5680	BM	substance[329]	giv[329]	_	_
34-8	5681-5683	as	_	_	_	_
34-9	5684-5691	primary	_	_	_	_
34-10	5692-5698	source	_	_	_	_
34-11	5699-5701	of	_	_	_	_
34-12	5702-5706	stem	object[330]	giv[330]	_	_
34-13	5707-5712	cells	object[330]	giv[330]	_	_
34-14	5713-5716	and	_	_	_	_
34-15	5717-5721	they	person	giv	_	_
34-16	5722-5728	showed	_	_	_	_
34-17	5729-5735	fusion	abstract|abstract[333]	giv|new[333]	_	_
34-18	5736-5743	results	abstract[333]	new[333]	_	_
34-19	5744-5751	ranging	_	_	_	_
34-20	5752-5756	from	_	_	_	_
34-21	5757-5759	87	quantity[334]	new[334]	_	_
34-22	5760-5761	%	quantity[334]	new[334]	_	_
34-23	5762-5764	to	quantity[334]	new[334]	_	_
34-24	5765-5769	92.3	quantity[334]|quantity[335]	new[334]|new[335]	_	_
34-25	5770-5771	%	quantity[334]|quantity[335]	new[334]|new[335]	_	_
34-26	5772-5774	in	_	_	_	_
34-27	5775-5776	a	person[336]	new[336]	_	_
34-28	5777-5782	total	person[336]	new[336]	_	_
34-29	5783-5785	of	person[336]	new[336]	_	_
34-30	5786-5789	297	person[336]	new[336]	_	_
34-31	5790-5798	patients	person[336]	new[336]	_	_
34-32	5799-5800	.	_	_	_	_
